Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
26
AMLX Quote, Financials, Valuation and Earnings
Last price:
$12.03
Seasonality move
:
-35.89%
Day range:
$11.90 - $12.36
52-week range:
$2.60 - $16.96
Dividend yield:
0%
P/E ratio:
21.03x
P/S ratio:
7.31x
P/B ratio:
3.98x
Volume:
6.2M
Avg. volume:
1.5M
1-year change:
203.54%
Market cap:
$1.3B
Revenue:
$87.4M
EPS (TTM):
-$1.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals, Inc.
|
-- | -$0.27 | -100% | -31.47% | $20.22 |
|
AVTR
Avantor, Inc.
|
$1.6B | $0.20 | -2.99% | -70.55% | $13.32 |
|
BAX
Baxter International, Inc.
|
$2.6B | $0.50 | 2.57% | 118.69% | $23.67 |
|
HUM
Humana, Inc.
|
$35.4B | $10.64 | 9.8% | -30.6% | $287.83 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
TMCI
Treace Medical Concepts, Inc.
|
$52M | -$0.24 | -10.11% | -1650% | $5.27 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals, Inc.
|
$12.02 | $20.22 | $1.3B | 21.03x | $0.00 | 0% | 7.31x |
|
AVTR
Avantor, Inc.
|
$11.27 | $13.32 | $7.7B | 10.97x | $0.00 | 0% | 1.17x |
|
BAX
Baxter International, Inc.
|
$18.96 | $23.67 | $9.7B | 167.20x | $0.01 | 2.74% | 0.88x |
|
HUM
Humana, Inc.
|
$259.40 | $287.83 | $31.2B | 24.31x | $0.89 | 1.37% | 0.25x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.30 | $0.85 | $667.9M | 8.90x | $0.80 | 0% | 10.30x |
|
TMCI
Treace Medical Concepts, Inc.
|
$2.57 | $5.27 | $163.8M | -- | $0.00 | 0% | 0.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals, Inc.
|
1.76% | 1.940 | 0.4% | 13.34x |
|
AVTR
Avantor, Inc.
|
40.92% | 0.979 | 45.33% | 0.90x |
|
BAX
Baxter International, Inc.
|
57.29% | 0.027 | 83.18% | 0.96x |
|
HUM
Humana, Inc.
|
40.5% | 0.632 | 40.21% | 0.00x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
TMCI
Treace Medical Concepts, Inc.
|
44.1% | 1.305 | 16.46% | 2.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals, Inc.
|
-$120K | -$36M | -69.11% | -70.27% | 6113.38% | -$30.4M |
|
AVTR
Avantor, Inc.
|
$526.5M | $138.4M | -0.81% | -1.4% | 8.52% | $171.7M |
|
BAX
Baxter International, Inc.
|
$938M | $194M | -1.9% | -4.83% | 6.84% | $126M |
|
HUM
Humana, Inc.
|
-- | $400M | 4.25% | 7.3% | 0.41% | $836M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
TMCI
Treace Medical Concepts, Inc.
|
$39.7M | -$15.7M | -29.15% | -49.13% | -31.22% | -$11.9M |
Amylyx Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AMLX or AVTR?
Avantor, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of -43.84%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat Avantor, Inc.'s return on equity of -1.4%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M AVTRAvantor, Inc.32.42% -$1.04 $9.4B -
What do Analysts Say About AMLX or AVTR?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 68.24%. On the other hand Avantor, Inc. has an analysts' consensus of $13.32 which suggests that it could grow by 18.2%. Given that Amylyx Pharmaceuticals, Inc. has higher upside potential than Avantor, Inc., analysts believe Amylyx Pharmaceuticals, Inc. is more attractive than Avantor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 AVTRAvantor, Inc.4 13 1 -
Is AMLX or AVTR More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.02%.
-
Which is a Better Dividend Stock AMLX or AVTR?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMLX or AVTR?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 1.17x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M AVTRAvantor, Inc.1.17x 10.97x $1.6B -$711.8M
-
Which has Higher Returns AMLX or BAX?
Baxter International, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of -1.8%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat Baxter International, Inc.'s return on equity of -4.83%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M BAXBaxter International, Inc.33.09% $0.02 $16.9B -
What do Analysts Say About AMLX or BAX?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 68.24%. On the other hand Baxter International, Inc. has an analysts' consensus of $23.67 which suggests that it could grow by 24.82%. Given that Amylyx Pharmaceuticals, Inc. has higher upside potential than Baxter International, Inc., analysts believe Amylyx Pharmaceuticals, Inc. is more attractive than Baxter International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 BAXBaxter International, Inc.2 13 1 -
Is AMLX or BAX More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.771%.
-
Which is a Better Dividend Stock AMLX or BAX?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.01 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.
-
Which has Better Financial Ratios AMLX or BAX?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Baxter International, Inc. quarterly revenues of $2.8B. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is higher than Baxter International, Inc.'s net income of -$51M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 0.88x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M BAXBaxter International, Inc.0.88x 167.20x $2.8B -$51M
-
Which has Higher Returns AMLX or HUM?
Humana, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of 0.59%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat Humana, Inc.'s return on equity of 7.3%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M HUMHumana, Inc.-- $1.62 $31.2B -
What do Analysts Say About AMLX or HUM?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 68.24%. On the other hand Humana, Inc. has an analysts' consensus of $287.83 which suggests that it could grow by 10.96%. Given that Amylyx Pharmaceuticals, Inc. has higher upside potential than Humana, Inc., analysts believe Amylyx Pharmaceuticals, Inc. is more attractive than Humana, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 HUMHumana, Inc.7 16 1 -
Is AMLX or HUM More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.462, suggesting its less volatile than the S&P 500 by 53.84%.
-
Which is a Better Dividend Stock AMLX or HUM?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.37% to investors and pays a quarterly dividend of $0.89 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 35.45% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AMLX or HUM?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Humana, Inc. quarterly revenues of $32.6B. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is lower than Humana, Inc.'s net income of $194M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while Humana, Inc.'s PE ratio is 24.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 0.25x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M HUMHumana, Inc.0.25x 24.31x $32.6B $194M
-
Which has Higher Returns AMLX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of -255.85%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About AMLX or NBY?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 68.24%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Amylyx Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Amylyx Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is AMLX or NBY More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock AMLX or NBY?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMLX or NBY?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M NBYNovaBay Pharmaceuticals, Inc.10.30x 8.90x $521K -$1.3M
-
Which has Higher Returns AMLX or TMCI?
Treace Medical Concepts, Inc. has a net margin of -17476.92% compared to Amylyx Pharmaceuticals, Inc.'s net margin of -32.44%. Amylyx Pharmaceuticals, Inc.'s return on equity of -70.27% beat Treace Medical Concepts, Inc.'s return on equity of -49.13%.
Company Gross Margin Earnings Per Share Invested Capital AMLXAmylyx Pharmaceuticals, Inc.-94.47% -$0.37 $337.9M TMCITreace Medical Concepts, Inc.79.07% -$0.26 $159.6M -
What do Analysts Say About AMLX or TMCI?
Amylyx Pharmaceuticals, Inc. has a consensus price target of $20.22, signalling upside risk potential of 68.24%. On the other hand Treace Medical Concepts, Inc. has an analysts' consensus of $5.27 which suggests that it could grow by 105.06%. Given that Treace Medical Concepts, Inc. has higher upside potential than Amylyx Pharmaceuticals, Inc., analysts believe Treace Medical Concepts, Inc. is more attractive than Amylyx Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMLXAmylyx Pharmaceuticals, Inc.10 1 0 TMCITreace Medical Concepts, Inc.1 4 0 -
Is AMLX or TMCI More Risky?
Amylyx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Treace Medical Concepts, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AMLX or TMCI?
Amylyx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Treace Medical Concepts, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMLX or TMCI?
Amylyx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Treace Medical Concepts, Inc. quarterly revenues of $50.2M. Amylyx Pharmaceuticals, Inc.'s net income of -$34.4M is lower than Treace Medical Concepts, Inc.'s net income of -$16.3M. Notably, Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio is 21.03x while Treace Medical Concepts, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals, Inc. is 7.31x versus 0.74x for Treace Medical Concepts, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMLXAmylyx Pharmaceuticals, Inc.7.31x 21.03x -- -$34.4M TMCITreace Medical Concepts, Inc.0.74x -- $50.2M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
